Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 70 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Repatha Clear all

Conditions: Diabetes Mellitus, Type 2, Dyslipidemia Associated With Type II Diabetes Mellitus, Percutaneous Coronary Intervention
Interventions: Evolocumab, Placebo; Drug
Lead sponsor: Inova Health Care Services; Other
Eligibility: Not listed
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Falls Church, Virginia

Conditions: Familial Hypercholesterolemia
Interventions: Evolocumab; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Primary Hypercholesterolemia, Mixed Dyslipidemia
Interventions: Evolocumab Pre-filled Syringe, Evolocumab AI/pen; Biological
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 21
States / cities: Encino, California • Thousand Oaks, California • Ventura, California + 17 more

Conditions: Healthy Participants, Pharmacokinetics
Interventions: Evolocumab Drug Substance A, Evolocumab Drug Substance B; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 405 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 4
States / cities: Springfield, Missouri • Columbus, Ohio • Dallas, Texas + 1 more

Conditions: Healthy Subjects, Pharmacokinetics, Pharmacodynamics
Interventions: Evolocumab, Alirocumab, Placebo; Biological
Lead sponsor: Food and Drug Administration (FDA); Federal
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Atezolizumab, Cobimetinib, RO6958688, Docetaxel, CPI-444, Pemetrexed, Carboplatin, Gemcitabine, Linagliptin, Tocilizumab, Ipatasertib, Bevacizumab, Sacituzumab Govitecan, Radiation, Evolocumab, Tiragolumab, XL092, Camonsertib; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 4
States / cities: Las Vegas, Nevada • New York, New York • Cleveland, Ohio + 1 more

Conditions: Hyperlipidemia
Interventions: Evolocumab, Ezetimibe, Placebo to Evolocumab, Placebo to Ezetimibe; Biological · Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 615 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 47
States / cities: Birmingham, Alabama • Chandler, Arizona • Little Rock, Arkansas + 40 more

Conditions: Coronary Artery Disease
Interventions: Evolocumab Injections; Drug
Lead sponsor: Annapoorna Kini; Other
Eligibility: 18 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Peripheral Arterial Disease
Interventions: Evolocumab 140 mg/mL Subcutaneous Injection 1 milliliter (mL) pre-filled injector Pen x 3 for a monthly dose of 420 mg for 6 months., Placebo 1milliliter (mL) Subcutaneous Injection pre-filled injector Pen x 3 monthly for 6 months.; Drug · Other
Lead sponsor: Leonardo Clavijo; Other
Eligibility: 40 Years to 85 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy Participants
Interventions: Evolocumab Drug Substance A (Test), Evolocumab Drug Substance B (Reference); Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 405 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 4
States / cities: Anaheim, California • South Miami, Florida • Springfield, Missouri + 1 more

Conditions: Coronary Artery Bypass Graft Surgery, Atherosclerosis, Vein Occlusion
Interventions: Evolocumab, Placebo; Drug · Other
Lead sponsor: Unity Health Toronto; Other
Eligibility: 18 Years and older
Enrollment: 782 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 5
States / cities: San Francisco, California • Jacksonville, Florida • Portland, Maine + 2 more

Conditions: Hyperlipidemia, Mixed Dyslipidemia
Interventions: Evolocumab; Biological
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Primary Hypercholesterolemia, Mixed Dyslipidemia
Interventions: Evolocumab AMD, Evolocumab AI/pen; Biological
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 22
States / cities: Phoenix, Arizona • Encino, California • Thousand Oaks, California + 18 more

Conditions: Chronic Kidney Diseases, High Cholesterol
Interventions: Evolocumab, Placebo; Drug · Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 40 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 2
States / cities: Mineola, New York • New York, New York

Conditions: Hyperlipidemia and Mixed Dyslipidemia
Interventions: Evolocumab, Standard of Care; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 3,681 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 107
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 94 more

Conditions: Peripheral Arterial Disease
Interventions: Evolocumab; Drug
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Falls Church, Virginia

Conditions: Dyslipidemias
Interventions: obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks; Drug
Lead sponsor: NewAmsterdam Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypercholesterolemia
Interventions: Evolocumab, Standard of care; Biological · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 78
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 66 more

Conditions: Atherosclerotic Cardiovascular Disease
Interventions: NNC0385-0434 A 15 mg, NNC0385-0434 A 40 mg, Placebo I A (for NNC0385-0434 A 15 mg), NNC0385-0434 A 100 mg, Placebo I A (for NNC0385-0434 A 40 mg), Placebo II A (for NNC0385-0434 A 100 mg), Evolocumab 140 mg/mL, Repatha®; Drug · Other
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 40 Years and older
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 13
States / cities: Palm Springs, California • Boca Raton, Florida • Fort Lauderdale, Florida + 9 more

Conditions: Dyslipidemia
Interventions: Evolocumab; Biological
Lead sponsor: Amgen; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 5,035 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 144
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 136 more

Conditions: Subjects With Hyperlipidemia, Dyslipidemia
Interventions: Evolocumab, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 5
States / cities: Miami, Florida • Las Vegas, Nevada • Mooresville, North Carolina + 2 more

Conditions: Hypercholesterolemia, Cardiovascular Diseases
Interventions: lerodalcibep, evolocumab, alirocumab; Biological
Lead sponsor: LIB Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Cincinnati, Ohio

Conditions: Hypercholesterolemia
Interventions: Evolocumab, Placebo; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 970 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 59
States / cities: Huntsville, Alabama • Mobile, Alabama • Little Rock, Arkansas + 54 more

Conditions: Cardiovascular Diseases, Cardiovascular Morbidity, Coronary Heart Disease, Low-density-lipoprotein-type
Interventions: N/A - observational study.; Other
Lead sponsor: University of Sydney; Other
Eligibility: Not listed
Enrollment: 1,137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Effects of Evolocumab on Platelet Reactivity in Patients With Diabetes Mellitus

Impact of LDL-cholesterol Lowering on Platelet Activation

Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen

Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose

Pharmacodynamic Biomarkers to Support Biosimilar Development: PCSK9 Inhibitors

A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)

Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2

Effect of Evolocumab on Coronary Plaque Characteristics

Effect of Evolocumab in Functional Status and LDL Oxidation of Patients With Peripheral Arterial Disease

Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose.

Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery

Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab

Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen

Evolocumab In Advanced Chronic Kidney Disease Trial

Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia

Antiplatelet Effects of Evolocumab in Patients With Peripheral Arterial Disease

Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels

Open Label Study of Long Term Evaluation Against LDL-C Trial

A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))

Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients

GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound

Observational Study of Cardiovascular Disease.